Founded in Belgrade, United States, Xtant Medical Holdings, Inc. is dedicated to developing, acquiring, manufacturing, and commercializing regenerative surgical products. The company's core mission is to advance the treatment of degenerative, traumatic, and deformity conditions through innovative medical solutions. Xtant Medical's product portfolio includes offerings like SimpliGraft™ and SimpliMax™, designed to address chronic and acute wounds. Their market focus is primarily within the United States, serving healthcare providers and patients with cutting-edge regenerative technologies.
Xtant Medical has garnered attention from notable investors and industry leaders, contributing to its steady growth and market presence. The company has achieved significant milestones, such as reporting revenue growth and raising its full-year revenue guidance. These accomplishments underscore Xtant Medical's impact on the medical field, particularly in enhancing surgical outcomes and patient care through its regenerative products.